University of Birmingham
GPNMB: exploring a novel target for therapy in Hodgkin lymphoma
Abstract
dc:description.abstractGlycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein highly expressed in multiple tumours, including classical Hodgkin lymphoma (cHL); a tumour in which the malignant Hodgkin and Reed-Sternberg (HRS) cells rely on the tumour microenvironment (TME) to survive and evade detection by the host immune system. In this study, I explore the contribution of GPNMB to immune evasion of cHL as a novel therapeutic target. I have shown that GPNMB is highly expressed in tumour-associated macrophages (TAM) in cHL tissues but expression is highly variable. In vitro differentiation of macrophages (from CD14+ monocytes) was shown to be associated with an increase in GPNMB expression, including the generation of a soluble form of GPNMB (sGPNMB). sGPNMB partially inhibited T-cell activation and T-cell recognition of Epstein-Barr virus (EBV)-specific epitopes in cHL cell lines. Preliminary experiments indicated that the inhibition of T cell activation by GPNMB could be overcome with GPNMB neutralising antibodies. This work provides evidence in support of the hypothesis that GPNMB can mediate an immune checkpoint that inhibits anti-tumour cytotoxic T-lymphocytes (CTL). It provides a basis for further investigations designed to explore the therapeutic potential of targeting GPNMB in cHL.
Degree
thesis:*- Name dc:type.qualificationname
- d_ph
- Level dc:type.qualificationlevel
- d_ph
- Grantor dc:publisher.institution
- University of Birmingham
- Year dc:date.issued
- 2021
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Masand, Navta
Subjects
dc:subject × 3Rights
- Language dc:language.dcterms_iso639_2
- eng
Identifiers
dc:identifier.*- Dc Identifier Grantnumber
-
BCHRF457
CCLGA 2017 18